查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2034268

原發性膜性腎臟病（PMN）：新型療法、未滿足的需求和TPP洞察報告，2026年

Primary Membranous Nephropathy (PMN) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 54 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 2025年PMN治療市場價值為6.22億美元，預計2035年將達到31.8億美元。這意味著在預測期內將實現17.8%的強勁複合年成長率。
  • 在市場早期階段（2025-2027 年），ACE 抑制劑/ARB、皮質類固醇（潑尼松、Methylprednisolone）、免疫抑制劑（Cyclosporine、Tacrolimus、MMF）、Rituximab和 IVIG 等傳統治療方法將佔據主導地位。
  • 到 2035 年，新型生物製藥和標靶治療將主導市場，佔據大部分收入，從根本上改變治療模式。

原發性膜性腎臟病（PMN）的新治療方法和TPP見解

Thelansis 的《原發性膜性腎臟病(PMN) 新興治療方法、未滿足的需求和 TPP 洞察報告 - 2026》對該適應症的關鍵新興治療方法和主要藥物發現機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、試驗設計和關鍵意見領袖 (KOL) 的見解。

原發性膜腎臟病（PMN）概述

原發性膜性腎臟病（PMN）是一種特異性自體免疫腎絲球疾病，也是非糖尿病成人腎病變症候群的主要原因之一。臨床上，它表現為大量蛋白尿（≥3.5 g/天）、周邊水腫、低白蛋白血症、高血脂症以及血栓栓塞併發症（包括腎靜脈血栓症）風險增加。

其病理生理特徵是 IgG4 自體抗體和補體複合物（C5b-9 膜攻擊複合物）沉積在腎小球基底膜上皮下，導致足細胞損傷和濾過屏障破壞。

現代多形核白血病 (PMN) 的分類是基於其分子機制。約 70-80% 的病例與抗 PLA2R（M 型磷脂酶 A2 受體）抗體相關，約 1-5% 的病例與抗 THSD7A 抗體相關。這種分子層面的認知顯著改變了疾病管理，使得透過血清學檢測進行非侵入性診斷成為可能，並可利用抗體滴度進行疾病後續觀察和風險分層。

多形性嗜中性球性腎病變（PMN）主要影響成人，發生率在中老年人群最高。診斷主要透過血清學檢測，必要時可進行切片檢查。

治療策略包括支持性治療（血管緊張素轉換酶抑制劑、血管緊張素受體阻斷劑、他汀類藥物、利尿劑）和免疫抑制療法，包括糖皮質激素、Calcineurin抑制劑和單株抗體。特別是，利Rituximab等B細胞清除療法是現代治療的核心，能夠實現標靶免疫緩解。

儘管取得了進展，但 PMN 仍然是一種慢性複發性疾病，發展為慢性腎臟病(CKD) 或末期腎功能衰竭(ESRD) 的風險仍然存在，因此對新的標靶治療的需求日益成長。

主要亮點

  • 據估計，到 2025 年，美國患有 PMN 的人數為 86,410 人，預計到 2035 年將增加到 97,845 人，反映出疾病負擔的穩定增加。
  • 預計2025年新確診患者人數為3,297人，2035年為3,546人，顯示診斷率將逐漸上升。
  • PMN 在女性中更為常見，預計到 2025 年女性病例為 34,996 例，男性病例為 51,414 例，預計到 2035 年這一差距將進一步擴大（女性病例為 39,627 例，男性病例為 58,218 例）。
  • 患者平均年齡為 48 歲，疾病負擔最重的人集中在 55 歲以上。
  • 這種疾病是慢性進行性，相當一部分患者需要長期接受免疫抑制治療，因此對治療的需求持續存在。

基於對醫生和關鍵意見領袖（KOL）的調查得出的結論：

  • 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更深入的見解，從而進一步豐富了研究成果。
  • 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

  • PowerPoint簡報
  • MS Excel

主要問題

  • 詳細的競爭格局趨勢
  • 管道分析
  • 符合新興治療方法的患者
  • 主要企業
  • 主要作用機制
  • 發布日期等的預測
  • 臨床試驗趨勢分析
  • 目標患者群
  • 試驗終點
  • 測試設計
  • 受試者招募標準等。
  • 未滿足的需求和機遇
  • 目前主要治療方法的有效性
  • 未滿足需求的關鍵領域
  • 估算主要未滿足需求的市場規模
  • 目標產品概況
  • 屬性和級別
  • 醫生開立的處方
  • 預期患者佔有率
  • 關鍵KOL洞察對領先新興治療方法的見解
  • 意識
  • 預期用途/處理線
  • 對主要未滿足需求的滿意度
  • KOL評論

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • Alexion Pharmaceuticals, Inc.
  • Excyte Biopharma Ltd
  • Climb Bio, Inc.
  • Cerium Pharmaceuticals
  • Vertex Pharmaceuticals Incorporated
  • argenx
  • BioRay Pharmaceutical Co., Ltd.
  • Shanghai JMT-Bio Inc.
  • Beijing Mabworks Biotech Co., Ltd.
  • Biogen
  • Guangdong Hengrui Pharmaceutical Co., Ltd
  • BeOne Medicines
  • Hoffmann-La Roche
  • Everest Medicines（China）Co.,Ltd.
  • Nkarta, Inc.
  • Walden Biosciences
  • Apellis Pharmaceuticals, Inc.
  • Alpine Immune Sciences, Inc.
  • Vera Therapeutics, Inc.
  • Reistone Biopharma Company Limited

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
  • 新興治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 領先的新興治療方法—概述和KOL洞察

第3章 產品屬性分析

  • 重點
  • 科學屬性
  • 商業性屬性
  • 產品定位

第4章：初步調查

  • 目前治療狀態
  • 主要治療方法與目標患者族群的比較
  • 主要特點和優勢
  • 未來治療環境
  • 當前挑戰
  • 未滿足的需求
  • 新興治療方法
  • 主要治療方法與目標患者族群的比較
  • 主要特點和優勢
  • 未來治療前景
  • 未滿足的需求和關鍵意見領袖的期望

第5章：未滿足的需求和TPP分析

  • 新興治療方法的主要未滿足需求和未來成就
  • TPP分析與KOL預期

第6章 監理與報銷環境

第7章附錄

簡介目錄

Primary Membranous Nephropathy (PMN) Emerging Therapy and TPP Insights

Thelansis's "Primary Membranous Nephropathy (PMN) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Primary Membranous Nephropathy (PMN) Overview

Primary Membranous Nephropathy (PMN) is a specific, autoimmune-mediated glomerular disease and a leading cause of nephrotic syndrome in non-diabetic adults. Clinically, it presents with massive proteinuria (>3.5 g/day), peripheral edema, hypoalbuminemia, hyperlipidemia, and an increased risk of thromboembolic complications, including renal vein thrombosis.

The pathophysiology is characterized by subepithelial deposition of IgG4 autoantibodies and complement complexes (C5b-9 membrane attack complex) along the glomerular basement membrane, leading to podocyte injury and disruption of the filtration barrier.

Modern classification of PMN is based on its molecular drivers. Approximately 70-80% of cases are associated with anti-PLA2R (M-type phospholipase A2 receptor) antibodies, while ~1-5% are linked to THSD7A antibodies. This molecular understanding has significantly transformed disease management, enabling non-invasive diagnosis through serological testing and the use of antibody titers for disease monitoring and risk stratification.

PMN predominantly affects adults, with peak incidence in middle-aged and older populations. Diagnosis is supported by serology and, where required, kidney biopsy.

Treatment strategies include supportive therapy (ACE inhibitors, ARBs, statins, diuretics) and immunosuppressive regimens, including corticosteroids, calcineurin inhibitors, and monoclonal antibodies. Notably, B-cell depleting therapies such as rituximab have become central to modern management, enabling targeted immunological remission.

Despite advances, PMN remains a chronic, relapsing condition, with ongoing risk of progression to chronic kidney disease (CKD) or end-stage renal disease (ESRD), driving continued need for novel targeted therapies.

Key Highlights

  • The diagnosed prevalent PMN population in the United States is estimated at 86,410 in 2025, increasing to 97,845 by 2035, reflecting steady disease burden growth.
  • The incident diagnosed population grows from 3,297 cases in 2025 to 3,546 cases by 2035, indicating gradual increase in diagnosis rates.
  • PMN shows a strong female predominance, with 34,996 female vs 51,414 male cases in 2025, widening further by 2035 (39,627 females vs 58,218 males).
  • The average age of patients is 48 years, with the highest disease burden concentrated in >=55 years age group.
  • The disease is chronic and progressive, with a significant proportion of patients requiring long-term immunosuppressive therapy, contributing to sustained treatment demand.

Market Overview

  • The PMN treatment market is valued at $622M in 2025, projected to reach $3.18Bn by 2035, representing a robust CAGR of 17.8% over the forecast period.
  • Early-stage market (2025-2027) is dominated by conventional therapies, including: ACE inhibitors / ARBs, Corticosteroids (prednisone, methylprednisolone), Immunosuppressants (cyclosporine, tacrolimus, MMF), Rituximab and IVIG
  • By 2035, novel biologics and targeted therapies dominate the market, accounting for the majority of revenue share, significantly shifting the treatment paradigm.

Insights driven by surveys* with physician / key opinion leaders:

  • Survey findings are corroborated and enriched by insights from interviews with leading KOLs
  • Survey is customized based on client requirements

Deliverables format:

  • PowerPoint presentation
  • MS Excel

Key business questions answered:

  • Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
  • Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
  • Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
  • Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
  • KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • Alexion Pharmaceuticals, Inc.
  • Excyte Biopharma Ltd
  • Climb Bio, Inc.
  • Cerium Pharmaceuticals
  • Vertex Pharmaceuticals Incorporated
  • argenx
  • BioRay Pharmaceutical Co., Ltd.
  • Shanghai JMT-Bio Inc.
  • Beijing Mabworks Biotech Co., Ltd.
  • Biogen
  • Guangdong Hengrui Pharmaceutical Co., Ltd
  • BeOne Medicines
  • Hoffmann-La Roche
  • Everest Medicines (China) Co.,Ltd.
  • Nkarta, Inc.
  • Walden Biosciences
  • Apellis Pharmaceuticals, Inc.
  • Alpine Immune Sciences, Inc.
  • Vera Therapeutics, Inc.
  • Reistone Biopharma Company Limited

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

  • Key takeaways
  • Scientific attributes
  • Commercial attributes
  • Product positioning

4. Primary Market Research

  • Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
  • Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)